Literature DB >> 16795058

Pulmonary hypertension in thalassemia: association with platelet activation and hypercoagulable state.

Sylvia T Singer1, Frans A Kuypers, Lori Styles, Elliott P Vichinsky, Drucella Foote, Howard Rosenfeld.   

Abstract

The pathogenesis of pulmonary hypertension (PAH), a serious complication in thalassemia, is not well understood. Thromboembolism has been postulated as one of the causative factors; however, there are currently limited specific data on its role. To examine whether increased platelet activation and hypercoagulability are linked to PAH, 25 beta-thalassemia major and beta-thalassemia intermedia patients were evaluated with Doppler echocardiograms for estimation of pulmonary artery pressure and with laboratory assays for indications of a prothrombotic state. The association of clinical variables and abnormal coagulation assays with PAH was determined. PAH was identified in 17 (68%) patients; mean pulmonary artery systolic pressure was 39.8 +/- 5.4 mm Hg. PAH was significantly associated with prior splenectomy, older age, and evidence for chronic hemolysis, diagnosed in both transfused (n = 10) and nontransfused (n = 7) patients. Increased platelet activation, measured by P-selectin, was significantly associated with PAH (P = 0.001). Increased thrombin-antithrombin III level was more prevalent in the presence of PAH, but increased fibrinolysis or low protein C levels were not. This study underscores the role of platelet activation in the development of PAH and stresses its occurrence even among patients who are regularly transfused, especially those who are older and have had splenectomies. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16795058     DOI: 10.1002/ajh.20640

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  36 in total

Review 1.  β-thalassemia intermedia: a clinical perspective.

Authors:  Khaled M Musallam; Ali T Taher; Eliezer A Rachmilewitz
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

2.  Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia.

Authors:  Claudia R Morris; Hae-Young Kim; Elizabeth S Klings; John Wood; John B Porter; Felicia Trachtenberg; Nancy Sweeters; Nancy F Olivieri; Janet L Kwiatkowski; Lisa Virzi; Kathryn Hassell; Ali Taher; Ellis J Neufeld; Alexis A Thompson; Sandra Larkin; Jung H Suh; Elliott P Vichinsky; Frans A Kuypers
Journal:  Br J Haematol       Date:  2015-04-24       Impact factor: 6.998

3.  A thalassaemia intermedia case with concomitant left atrial thrombus.

Authors:  Cem Sahin; Ozcan Basaran; Yasar Topal; Fatih Akin
Journal:  BMJ Case Rep       Date:  2014-06-20

4.  High levels of zinc-protoporphyrin identify iron metabolic abnormalities in pulmonary arterial hypertension.

Authors:  Ilka Decker; Sudakshina Ghosh; Suzy A Comhair; Samar Farha; Wai Hong Wilson Tang; Margaret Park; Sihe Wang; Alan E Lichtin; Serpil C Erzurum
Journal:  Clin Transl Sci       Date:  2011-08       Impact factor: 4.689

5.  The life of patients with thalassemia major.

Authors:  Caterina Borgna-Pignatti
Journal:  Haematologica       Date:  2010-03       Impact factor: 9.941

6.  Computed tomography-measured pulmonary artery to aorta ratio and EUTOS score for detecting dasatinib-induced pulmonary arterial hypertension.

Authors:  Takumi Toya; Yuji Nagatomo; Kazuki Kagami; Midori Yukino; Risako Yasuda; Takayuki Namba; Yasuo Ido; Shinichi Kobayashi; Nobuyuki Masaki; Hirotaka Yada; Fumihiko Kimura; Takeshi Adachi
Journal:  Int J Cardiovasc Imaging       Date:  2019-02-04       Impact factor: 2.357

Review 7.  Cardiac complications in thalassemia major.

Authors:  John C Wood
Journal:  Hemoglobin       Date:  2009       Impact factor: 0.849

8.  Pulmonary hypertension in well-transfused thalassemia major patients.

Authors:  Antonella Meloni; Jon Detterich; Alessia Pepe; Paul Harmatz; Tom D Coates; John C Wood
Journal:  Blood Cells Mol Dis       Date:  2014-11-24       Impact factor: 3.039

9.  Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension.

Authors:  Claudia R Morris; Hae-Young Kim; John Wood; John B Porter; Elizabeth S Klings; Felicia L Trachtenberg; Nancy Sweeters; Nancy F Olivieri; Janet L Kwiatkowski; Lisa Virzi; Sylvia T Singer; Ali Taher; Ellis J Neufeld; Alexis A Thompson; Vandana Sachdev; Sandra Larkin; Jung H Suh; Frans A Kuypers; Elliott P Vichinsky
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

Review 10.  Pleiotropic effects of intravascular haemolysis on vascular homeostasis.

Authors:  Gregory J Kato; James G Taylor
Journal:  Br J Haematol       Date:  2009-12-01       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.